Richmond Pharmacology appoints Dr Edward Jackson as Medical Director
Charlie Blackie-Kelly | November 7, 2025 | Appointment | | CRO, Richmond Pharmacology, biotech, clinical trials
Richmond Pharmacology, a contract research organisation (CRO) specialising in first-in-human and adaptive clinical trials, has appointed Dr Edward Jackson as Medical Director.
Chief Medical Director, Dr Ulrike Lorch, said: “We’re very pleased to welcome Dr Edward Jackson back to Richmond. His experience in early-phase research and translational science will strengthen our clinical programmes, particularly in non-interventional and rare disease studies.”
Dr Jackson originally joined Richmond Pharmacology in 2021 after six years at the NHS. He began as a Specialist Research Physician before being promoted to Associate Medical Director in 2023, contributing to a broad portfolio of clinical trials.
He returns to the company after a year at Owlstone Medical, a biotechnology firm developing breath-based diagnostics for disease detection, where he served as Associate Medical Director. During his time at Owlstone, Dr Jackson focused on oncology and hepatology translational research, as well as advancing his work in diagnostic device development.
Richmond Pharmacology reported that his new role will focus on developing and expanding the CRO’s non-interventional study portfolio and strengthening its capabilities in rare disease interventional trials. He will also spearhead the integration of AI technologies across the company’s clinical research programmes.
Dr Jackson commented: “I’m excited to return to Richmond Pharmacology and contribute to its continued growth in pioneering, data-enabled research. My focus will be on embedding real-world evidence and AI tools into our trial frameworks, especially in the rare disease space, where thoughtful innovation can make a real difference to patients.”
This article featured in: December 2025 – The Pharmafile Brief
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
